Seminars in arthritis and rheumatism
Can we modulate the gut microbiome to enhance DMARD efficacy in rheumatoid arthritis?
Promises and pitfalls of artificial intelligence models in forecasting rheumatoid arthritis treatment response and outcomes.
Initiation of glucocorticoids before entering rheumatology care associates with long-term glucocorticoid use in older adults with early rheumatoid arthritis: A joint analysis of Medicare and the Rheumatology Informatics System for Effectiveness (RISE) dat
The association of TNF inhibitor use with incident cardiovascular events in radiographic axial spondyloarthritis.
Multimorbidity phenotypes in ankylosing spondylitis and their association with disease activity and functional impairment: Data from the prospective study of outcomes in ankylosing spondylitis cohort.
The ASAS-OMERACT core domain set for axial spondyloarthritis.
Metrics and definitions used in the assessment of cognitive impairment in systemic lupus erythematosus: A systematic review.
The economic burden of systemic lupus erythematosus in commercially- and medicaid-insured populations in the United States.
RISE registry reveals potential gaps in medication safety for new users of biologics and targeted synthetic DMARDs.
Longitudinal disease- and steroid-related damage among adults with childhood-onset systemic lupus erythematosus.
